Published in N Engl J Med on September 08, 2014
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med (2017) 4.55
Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation. Neuron (2015) 2.09
Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol (2015) 1.70
Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int (2014) 1.61
Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation. Am J Respir Crit Care Med (2015) 1.49
Antibodies to watch in 2015. MAbs (2015) 1.28
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov (2015) 1.05
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax (2015) 1.04
Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm (2015) 0.97
Eosinophils in mucosal immune responses. Mucosal Immunol (2015) 0.97
Development of New Therapies for Severe Asthma. Allergy Asthma Immunol Res (2017) 0.94
Current concepts of severe asthma. J Clin Invest (2016) 0.91
Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract (2015) 0.90
Dusp5 negatively regulates IL-33-mediated eosinophil survival and function. EMBO J (2014) 0.87
Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study. Respir Res (2015) 0.87
Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J (2016) 0.86
Elucidating novel disease mechanisms in severe asthma. Clin Transl Immunology (2016) 0.84
A pilot study of symptom profiles from a polyp vs an eosinophilic-based classification of chronic rhinosinusitis. Int Forum Allergy Rhinol (2015) 0.84
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol (2016) 0.84
Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation. Front Immunol (2015) 0.84
Tailored therapy for severe asthma. Multidiscip Respir Med (2015) 0.83
Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release (2016) 0.82
Eosinophilic bioactivities in severe asthma. World Allergy Organ J (2016) 0.82
Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther (2014) 0.81
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy (2016) 0.81
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis (2016) 0.81
The immunology of asthma: Asthma phenotypes and their implications for personalized treatment. Ann Allergy Asthma Immunol (2016) 0.81
Unlocking proteomic heterogeneity in complex diseases through visual analytics. Proteomics (2015) 0.81
Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med (2014) 0.80
STAT6 Regulates the Development of Eosinophilic versus Neutrophilic Asthma in Response to Alternaria alternata. J Immunol (2016) 0.80
Anti-IL5 therapy for asthma and beyond. World Allergy Organ J (2014) 0.79
IgE-activated basophils regulate eosinophil tissue entry by modulating endothelial function. J Exp Med (2015) 0.79
Thiol redox chemistry: role of protein cysteine oxidation and altered redox homeostasis in allergic inflammation and asthma. J Cell Biochem (2015) 0.79
Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res (2015) 0.79
Using Periostin as a Biomarker in the Treatment of Asthma. Allergy Asthma Immunol Res (2016) 0.79
Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res (2016) 0.79
Clinical Characteristics of Exacerbation-Prone Adult Asthmatics Identified by Cluster Analysis. Allergy Asthma Immunol Res (2017) 0.78
Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy (2016) 0.78
Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice. Allergy (2016) 0.78
Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther (2015) 0.78
Achieving asthma control: Providing a framework for clinicians. Ann Thorac Med (2016) 0.78
Update on reslizumab for eosinophilic asthma. Expert Opin Biol Ther (2015) 0.78
Novel Therapies for Eosinophilic Disorders. Immunol Allergy Clin North Am (2015) 0.78
The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy (2015) 0.77
Findings from a pilot Randomised trial of an Asthma Internet Self-management Intervention (RAISIN). BMJ Open (2016) 0.77
Methylation of Gata3 protein at Arg-261 regulates transactivation of the Il5 gene in T helper 2 cells. J Biol Chem (2015) 0.77
Novel strategies for the treatment of asthma. Allergo J Int (2016) 0.76
Asthma heterogeneity and severity. World Allergy Organ J (2016) 0.76
Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res (2015) 0.76
The Therapeutic Potential of Targeting Cytokine Alarmins to Treat Allergic Airway Inflammation. Front Physiol (2016) 0.76
Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol (2016) 0.76
Human and Mouse Eosinophils Have Antiviral Activity against Parainfluenza Virus. Am J Respir Cell Mol Biol (2016) 0.76
Deciphering Asthma Biomarkers with Protein Profiling Technology. Int J Inflam (2015) 0.76
Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. Biomark Insights (2016) 0.76
Profile of lebrikizumab and its potential in the treatment of asthma. J Asthma Allergy (2015) 0.76
The transition of sputum inflammatory cell profiles is variable in stable asthma patients. Asia Pac Allergy (2017) 0.75
Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies. Ann Allergy Asthma Immunol (2016) 0.75
Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease. Transfus Med Hemother (2016) 0.75
Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract (2016) 0.75
Bronchial thermoplasty in asthma: current perspectives. J Asthma Allergy (2015) 0.75
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? Front Immunol (2017) 0.75
Mepolizumab (Nucala) For Severe Eosinophilic Asthma. P T (2016) 0.75
Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy (2015) 0.75
The Regulatory Function of Eosinophils. Microbiol Spectr (2016) 0.75
Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res (2016) 0.75
New and emerging therapies for asthma. Ann Allergy Asthma Immunol (2016) 0.75
T-cell-intrinsic Tif1α/Trim24 regulates IL-1R expression on TH2 cells and TH2 cell-mediated airway allergy. Proc Natl Acad Sci U S A (2016) 0.75
Severe asthma gets first biologic in decades. Nat Biotechnol (2016) 0.75
Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respir Res (2016) 0.75
Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Destination Airway: Tracking Granulocytes in Asthma. EBioMedicine (2014) 0.75
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Nothing New Under the Sun. Immunol Allergy Clin North Am (2016) 0.75
Therapeutic interventions in severe asthma. World Allergy Organ J (2016) 0.75
The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med (2017) 0.75
Reslizumab in the management of poorly controlled asthma: the data so far. J Asthma Allergy (2016) 0.75
Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol (2016) 0.75
Mepolizumab. Aust Prescr (2017) 0.75
Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv Chronic Dis (2016) 0.75
[Asthma: how does mepolizumab affect exacerbations and need for steroids? Mepolizumab is a new therapeutic option in severe asthma [corrected]]. Dtsch Med Wochenschr (2014) 0.75
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open (2016) 0.75
Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther Clin Risk Manag (2016) 0.75
Variability of blood eosinophil count as an asthma biomarker. Ann Allergy Asthma Immunol (2016) 0.75
Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. Int J Mol Sci (2017) 0.75
CXC chemokine superfamily induced by Interferon-γ in asthma: a cross-sectional observational study. Asthma Res Pract (2016) 0.75
Relationship of Allergy with Asthma: There Are More Than the Allergy "Eggs" in the Asthma "Basket". Front Pediatr (2017) 0.75
Current and emerging treatments for severe asthma. J Thorac Dis (2015) 0.75
Update on the Management of Aspirin-Exacerbated Respiratory Disease. Allergy Asthma Immunol Res (2016) 0.75
Targeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review. P T (2017) 0.75
Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
High Density Lipoproteins and Type 2 Inflammatory Biomarkers are Negatively Correlated in Atopic Asthmatics. J Lipid Res (2017) 0.75
The Biology of Eosinophils and Their Role in Asthma. Front Med (Lausanne) (2017) 0.75
Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol (2017) 0.75
Asthma Endotypes and an Overview of Targeted Therapy for Asthma. Front Med (Lausanne) (2017) 0.75
ATS-NHLBI Asthma COPD Overlap (ACO) Workshop Report. Am J Respir Crit Care Med (2017) 0.75
The Pharmaceutical Industry Needs More Clinical Pharmacologists. Br J Clin Pharmacol (2017) 0.75
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne) (2017) 0.75
Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? J Asthma Allergy (2017) 0.75
Newly Divided Eosinophils Limit Ozone-Induced Airway Hyperreactivity In Non-Sensitized Guinea Pigs. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet (2002) 8.57
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med (2009) 6.84
Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med (2002) 6.52
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
Does this dyspneic patient in the emergency department have congestive heart failure? JAMA (2005) 6.14
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med (2009) 4.83
Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med (2006) 4.83
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol (2002) 4.79
Asthma control during the year after bronchial thermoplasty. N Engl J Med (2007) 4.79
Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet (2009) 4.56
Genome-wide association study identifies five loci associated with lung function. Nat Genet (2009) 4.10
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Adult Asthma Consensus Guidelines update 2003. Can Respir J (2004) 3.61
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Corticosteroids and the risk of atrial fibrillation. Arch Intern Med (2006) 3.28
Economic burden of asthma: a systematic review. BMC Pulm Med (2009) 3.10
Delay in diagnosis among hospitalized patients with active tuberculosis--predictors and outcomes. Am J Respir Crit Care Med (2002) 3.10
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol (2004) 2.93
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation (2012) 2.87
We should prohibit warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2015) 2.63
Prevalence, pathogenesis, and causes of chronic cough. Lancet (2008) 2.60
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med (2014) 2.53
A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol (2009) 2.53
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.52
Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol (2006) 2.49
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 2.48
New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest (2004) 2.47
The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med (2007) 2.44
The structural basis of airways hyperresponsiveness in asthma. J Appl Physiol (1985) (2006) 2.40
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest (2009) 2.40
Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res (2006) 2.40
Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax (2007) 2.37
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med (2012) 2.36
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J (2006) 2.34
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health (2005) 2.32
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat (2006) 2.30
Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest (2010) 2.29
Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med (2009) 2.27
Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 2.26
Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med (2014) 2.15
CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 2.15
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.13
C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2011) 2.12
Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med (2008) 2.09
T-helper 17 cell polarization in pulmonary arterial hypertension. Chest (2015) 2.09
Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med (2011) 2.07
Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med (2003) 1.98
Activation of the WNT/β-catenin pathway attenuates experimental emphysema. Am J Respir Crit Care Med (2010) 1.94
Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res (2004) 1.92
Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J (2013) 1.92
Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol (2008) 1.92
TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol (2002) 1.92
Preoperative pulmonary rehabilitation in patients undergoing lung resection for non-small cell lung cancer. Eur J Cardiothorac Surg (2007) 1.91
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol (2006) 1.91
IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med (2010) 1.91
Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest (2008) 1.89
Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology (2005) 1.88
Of flies, mice and men: a systematic approach to understanding the early life origins of chronic lung disease. Thorax (2012) 1.88
Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med (2012) 1.87
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med (2006) 1.86
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med (2012) 1.85
The influence of age on induced sputum differential cell counts in normal subjects. Chest (2004) 1.82
Statins in COPD: a systematic review. Chest (2009) 1.82
Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax (2011) 1.80
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation (2006) 1.79
Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. Phys Ther (2007) 1.77
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2002) 1.77
Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum (2013) 1.73
Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol (2007) 1.71
Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med (2008) 1.71
Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization. Can Respir J (2009) 1.70
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat (2006) 1.69
Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med (2006) 1.68
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest (2012) 1.68
Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol (2009) 1.68
Role of nasal nitric oxide in the resolution of experimental rhinovirus infection. J Allergy Clin Immunol (2004) 1.67
Risk factors of hospitalization and readmission of patients with COPD exacerbation--systematic review. Int J Chron Obstruct Pulmon Dis (2007) 1.67
Identification and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol (2004) 1.66
Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest (2005) 1.66